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Abstract 
Valproic acid (VPA) is used worldwide to treat epilepsy, migraine headaches and bipolar 
disorder. However, VPA is teratogenic and in utero exposure can lead to congenital 
malformations. Using inbred C57BL/6J (B6) and DBA/2J (D2) mice, we asked whether genetic 
variation could play a role in susceptibility to VPA teratogenesis. While B6 fetuses were more 
susceptible than D2 fetuses to digit and vertebral malformations, D2 fetuses were more 
susceptible to rib malformations. In a reciprocal cross between B6 and D2, genetically identical 
F1 mice carried in a B6 mother had a greater percentage of vertebral malformations following 
prenatal VPA exposure than F1 mice carried in a D2 mother. This reciprocal F1 difference is 
known as a maternal effect and shows that maternal genotype/uterine environment is an 
important mediator of VPA teratogenecity. VPA is a histone deacetylase inhibitor and it is 
possible that the differential teratogenesis in B6 and D2 is due to strain differences in histone 
acetylation. We observed strain differences in acetylation of histones H3 and H4 in both embryo 
and placenta following in utero VPA exposure, but additional studies are needed to determine 
the significance of these changes in mediating teratogenesis. Our results provide additional 
support that genetic factors, both maternal and fetal, play a role in VPA teratogenesis. Lines of 
mice derived from B6 and D2 will be a useful model for elucidating the genetic architecture 
underlying susceptibility to VPA teratogenesis.     
Valproic acid (VPA) is one of the most frequently used anti-epileptic drugs (AEDs) worldwide 
and has developed into a first-line treatment for migraine headaches and mania associated with 
bipolar disorder. While VPA has a good side-effect profile with little sedation and few 
behavioral effects, it is teratogenic. In utero VPA exposure can produce growth retardation and 
congenital malformations, including facial dysmorphology, spina bifida and other neural tube 
defects (NTDs), urogenital abnormalities, heart anomalies and skeletal malformations (Duncan, 
2007; Meador et al., 2008b). Recently revised estimates indicate that in the United States, there 
are one-half million women of childbearing age with epilepsy, most requiring AEDs; they give 
birth to 25,000 offspring each year (Harden et al., 2009; Meador et al., 2008a). The number of 
children exposed to AEDs in utero is likely double that because of AED use in treating mood 
disorders and migraines (Pennell, 2004). VPA warrants particular attention because it is more 
teratogenic than other AEDs (Harden et al., 2009; Meador et al., 2008a, 2008b), and an 
increasing number of women of reproductive age are taking VPA for various therapeutic reasons 
(Koren et al., 2006).  
The vast majority of women who take VPA during pregnancy give birth to normal children. It 
is likely that many factors play a role in susceptibility to the teratogenic effects of VPA. Studies, 
while few in number, have shown that genetic variation can play a role in the development of 
morphological and cognitive/behavioral abnormalities in children exposed to VPA in utero 
(Hockey et al., 1996; Kini et al., 2007; Kozma, 2001; Malm et al., 2002). Animal models have 
shown conclusively that genotype can affect susceptibility to VPA teratogenesis. Inbred strains 
of mice differ on several teratogenic outcomes, including skeletal malformations and NTDs 
(Faiella et al. 2000; Finnell et al., 1988). Significant changes in expression of many genes have 
also been reported following prenatal VPA exposure (Kultima et al., 2004; Massa et al., 2005). 
While genetic variation in VPA teratogenesis has been observed, the range of variation has not 
been well characterized, in humans or mice, and susceptibility genes remain unknown. 
We examined skeletal teratogenesis in inbred C57BL/6J (B6) and DBA/2J (D2) mice 
following in utero exposure to one of several doses of VPA. We chose B6 and D2 because they 
have been among the most widely used inbred strains of mice in biomedical research. Their 
genomes have been well-characterized, which makes lines of mice derived from them valuable 
for identifying genetic variation mediating many traits. In order to investigate the effects of 
maternal genotype and uterine environment on VPA teratogenesis, we reciprocally mated B6 and 
D2 and examined F1 litters. Valproic acid is a histone deacetylase inhibitor and increased histone 
acetylation/deacetylation inhibition has been linked to VPA teratogenesis (Eikel et al., 2006; 
Menegola et al., 2005). Therefore, we used Western blotting to quantify changes in acetylation 
of histone proteins H3 and H4 following prenatal VPA in both embryo and placenta. Finally, we 
looked at mRNA levels of several histone deacetylase genes following prenatal VPA.       
 Materials and Methods 
Dose-Response Study. Male and female B6 and D2 mice were obtained from the Jackson 
Laboratory and housed in the animal facility at the Institute for Behavioral Genetics, Boulder, 
CO. Males were individually housed, while females were housed 3-5 per cage. Mice were 
maintained on a 12-hour light/dark cycle, with lights on at 7:00 am. The temperature was kept at 
a constant 22 + 2º C. All procedures were approved by the University of Colorado Institutional 
Animal Care and Use Committee, in accordance with the National Institute of Health guidelines.  
From 7:00 – 9:00 am, two females were placed with a male and then examined for a seminal 
plug as evidence of mating. The morning of plug detection was designated gestational day 0 (GD 
0). Mated females were weighed and single-housed. At noon on GD 9 females were weighed to 
ascertain a 2 g minimum weight gain as evidence of pregnancy. Dams were then given an 
intraperitoneal (ip) injection of either saline or 200 mg/kg (0.4 ml/kg), 400 mg/kg (0.8 ml/kg) or 
800 mg/kg (1.6 ml/kg) VPA (sodium salt, Sigma). On GD 18, females were sacrificed and 
caesarean-sectioned (c-sectioned) between 1:30 and 2:30 pm; uterine horns were exposed and a 
count was made of live, dead and resorbed fetuses. Live fetuses were weighed, sexed and 
examined for gross morphological malformations. Fetuses were eviscerated and placed in 95% 
alcohol for two weeks. They were subsequently macerated in a 1% KOH solution for 72 hours 
and then placed in a 1% KOH solution containing alizarin red for 6-8 hours. Stained fetuses were 
placed first in a 25% and then a 75% glycerin solution for subsequent skeletal examination.  
Maternal variables included maternal weight gain and prenatal mortality. Data were analyzed 
using analysis of variance (ANOVA) with strain (B6 or D2) and treatment (saline, 200, 400, 800 
mg/kg VPA) as between group factors. Offspring variables included fetal weight at c-section and 
digit, rib and vertebral malformations. Digit malformations included fused or missing digits. Rib 
malformations included fused, missing, bifurcated or wavy/bulbous ribs. Vertebral 
malformations included fused, missing or asymmetrical arches and centra. Between groups 
variables for offspring data included strain, treatment and sex. Litter means (percent litter 
malformed) were the unit of analysis and litters with only one live fetus were not used in 
analyses of offspring variables. With the exception of weight at c-section, we saw no effect of 
sex on any measures of teratogenesis, so we collapsed across sex for means in Table 2. Post-hoc 
analyses consisted of Bonferoni corrected t-tests (treatment) within strain.    
Reciprocal Cross. When it became apparent there was a strain difference in response to VPA, 
we reciprocally bred B6 and D2 mice. On GD 9, pregnant dams were ip injected with either 
saline or 600 mg/kg (1.2 ml/kg) VPA. We chose the 600 mg/kg dose because of the high rate of 
prenatal mortality at the 800 mg/kg dose (B6 = 41%, D2 = 31%). Dams were sacrificed on GD 
18 and fetuses prepared and examined as described above.  
Western Blots for Acetylated Histones. In order to investigate the effects of in utero VPA 
exposure on histone acetylation in B6 and D2, mice were mated as described above. At noon on 
GD 9, pregnant dams were intraperitoneally (ip) injected with 600 mg/kg VPA. We included two 
additional groups in this study, one group of pregnant dams that was intragastrically intubated 
with 5.8 g/kg ethanol (2.9 ml/kg) and one that received an isocaloric amount of maltose-dextrin 
(3.5 ml/kg), . We included these additional groups because we have previously shown that, 
similar to our findings with VPA, B6 are susceptible to digit and vertebral malformations 
following prenatal alcohol exposure, while D2 are resistant (Boehm et al., 1997; Downing and 
Gilliam, 1999). Strain differences in histone acetylation following prenatal VPA exposure and 
prenatal ethanol exposure, while far from conclusive, would suggest a possible common 
teratogenic mechanism.  
Four hours after intubation or injection, dams were sacrificed and embryos and placentae were 
excised and frozen. Three litters per strain and treatment were produced and within a litter, all 
embryos were pooled for protein extraction and all placentae were pooled for protein extraction. 
Tissues were minced with a scissors and then homogenized in a sucrose lysis buffer using a 
Teflon homogenizer. The homogenate was washed and nuclear and cytoplasmic fractions were 
separated using low-speed centrifugation. Nuclear pellets were re-suspended in an H2SO4 buffer 
and gently stirred on a shaker overnight at 4˚ C. Pelleted, non acid soluble proteins were 
removed by centrifugation and the supernatants containing the acid soluble proteins were 
precipitated with TCA. Precipitated proteins were then centrifuged and the subsequent protein 
pellet was washed by centrifugation in ice-cold acetone; this step was repeated twice. Pellets 
were then resuspended in 10mM tris HCL, stirred gently overnight at 4˚ C and stored at -80˚ C 
for subsequent analyses. Protein concentrations were determined using a BCA assay with bovine 
serum albumin (BSA) as the standard.   
Nuclear protein extracts (5 μg) were subjected to SDS-PAGE and transferred to nitrocellulose 
membranes (Invitrogen, LC2000). Membranes were blocked in TBS containing 5% powdered 
milk and 0.1% TWEEN 20. Membranes were then incubated with antibodies against histone H3 
(Abcam, ab1791; 1:2500 dilution), histone H4 (Upstate Biotechnology, 05-858; 1:2500 dilution), 
acetylated histone H3K9 (Abcam, ab4441; 1:2500 dilution) and acetylated H4 (Upstate 
Biotechnology, 06-866; 1:2500 dilution). The acetylated H4 antibody recognizes 4 different 
acetylated lysines in the first 19 amino acids. After incubation with a primary antibody, 
membranes were incubated with a secondary antibody (anti-rabbit IgG peroxidase, Sigma 
Aldrich #A0545) and visualized using an ECL Western Blotting Detection System (Amersham, 
RPN2132). Immunoreactive bands were visualized by exposure to autoradiographic film. Films 
were scanned and band densities were quantified using ImageJ software 
(http://rsb.info.nih.gov/ij).  
Quantitative PCR. We examined expression of several histone deacetylase genes following 
prenatal VPA or alcohol exposure. B6 and D2 mice were mated as described above. At noon on 
GD 9, pregnant dams were ip injected with 600 mg/kg VPA, or intragastrically intubated with 
either 5.8 g/kg ethanol or maltose-dextrin. Four hours later, dams were sacrificed and embryos 
and placentae were excised. Three litters per strain and treatment were produced and tissues were 
pooled for extraction. RNA was extracted using a Qiagen RNeasy Midi Kit. Total RNA was then 
reverse transcribed to generate single-stranded cDNA using a Promega ImProm II Reverse 
Transcription Kit. Primers for Hdac1, Hdac2, Hdac3, Hdac4 and Hdac8 were designed using 
Primer Express software (Applied Biosystems; ABI). Quantitative PCR was performed on 
cDNAs using SYBR green chemistry and an ABI Prism 7000 system. Relative quantification of 
mRNA levels was determined by normalizing against a control gene, Gapdh, using the 2-ΔΔCT 
method (Livak and Schmittgen 2001). All determinations were replicated 3 times.  
   We chose the four hour time point to examine changes in histone acetylation and gene 
expression for several reasons. While many studies have shown increased acetylation or changes 
in gene expression by exposing cell lines or embryos to VPA in culture, to the best of our 
knowledge, only one study has looked at acetylation in vivo in mouse embryos following an 
acute dose of VPA prenatally (Menegola et al. 2005); they showed increased acetylation one 
hour after VPA exposure. The Menegola laboratory has also observed increased acetylation in 
embryos exposed to other HDAC inhibitors in utero at several different timepoints, including 4 
hours later (DiRenzo et al. 2007a, b, 2008). Two studies have examined changes in gene 
expression in mouse embryos following an acute doe of VPA in utero (Massa et al. 2005; 
Stodgell et al. 2006) and have shown changes in expression at the four hour time point. In our 
own work with C57BL/6J (B6) mice, we have shown changes in DNA methylation and gene 
expression in embryos four hours after intrauterine exposure to ethanol (Downing et al. in 
revision).   
Results 
Dose Response 
During pregnancy, B6 dams gained more weight than D2 dams (p < .01; Table 1). Compared 
to saline controls, only the 800 mg/kg dose of VPA significantly decreased weight gain (p < .01; 
Table 1) and increased embryolethality (p < .01; Table 1) in B6 and D2 litters. B6 fetuses 
exposed to either 400 or 800 mg/kg VPA weighed less than saline controls (p’s < .01; Table 1), 
while for D2, only the 800 mg/kg dose decreased fetal weight (p < .01; Table 1).  
D2 fetuses had a very low incidence of fused or missing digits after VPA treatment, while an 
increase was observed in B6 fetuses at 800 mg/kg (p < .01; Table 2). In utero VPA increased rib 
malformations only at the highest dose in B6 fetuses (p < .01), but both 400 and 800 mg/kg 
produced a significant increase in D2 (p’s < .01; Table 2). While VPA affected vertebral 
development in both B6 and D2, the effect was greater in B6. B6 fetuses had 39% and  94% 
vertebral malformation rates at the 400 and 800 mg/kg doses  (p’s < .01) while D2 had 28% and 
53% vertebral malformation rates at these doses (p’s < .02 and .01; Table 2). Indeed, following 
intrauterine exposure to 800 mg/kg VPA, most B6 fetuses had at least one vertebral defect.    
In addition to the malformations described above, we observed several other anomalies (data 
not shown). We found several supernumerary ribs; there were no differences between strains or 
among treatments. There are six components to the fetal sternum: the manubrium or first 
segment, segments two through five, and the xiphoid or sixth segment. Sternebral anomalies are 
not uncommon, even in unexposed mice, and are generally considered as variations rather than 
malformations; we did not include sternebral anomalies in vertebral or rib malformations 
described above. However, strernebral anomalies are frequently reported following in utero VPA 
exposure. We observed fused, bipartite, incompletely ossified and asymmetrical sternebrae in 
both strains. These sternebral anomalies occurred at a higher frequency in B6 fetuses and were 
observed at all doses, including saline. In addition, at the 800 mg/kg dose, two D2 and three B6 
fetuses had exencephaly.  
Reciprocal Cross 
We reciprocally mated B6 and D2, which produced B6D2 and D2B6 fetal genotypes (maternal 
genotype is first). On GD 9, dams were ip injected with saline or 600 mg/kg VPA. Dams were 
sacrificed on GD 18 and fetuses were processed and examined as described above. B6D2 dams 
gained more weight than D2B6 dams (p < .01) and saline-treated dams put on more weight than 
VPA-treated dams (p < .02), but there was no significant genotype x treatment interaction (Table 
1). Both genotypes had greater embryolethality when treated with VPA compared to saline 
controls (p < .02; Table 1). Saline-treated fetuses weighed more than VPA-treated fetuses (p < 
.01).  
Prenatal VPA exposure significantly increased digit malformations in B6D2 fetuses but not in 
D2B6 fetuses (p’s < .01 and .07, respectively; Table 2). While in utero VPA increased vertebral 
malformations in both B6D2 and D2B6 fetuses, the increase was greater in B6D2 fetuses (p < 
.01; Table 2). These results demonstrate that B6 maternal genotype and/or uterine environment 
increase susceptibility to digit and vertebral malformations, while the D2 genotype/uterine 
environment is less susceptible. There appears to be a threshold dose of VPA, somewhere 
between 400 and 600 mg/kg, above which fetuses carried in a B6 mother are particularly 
susceptible to vertebral malformations. B6 fetuses exposed to 400 mg/kg VPA had a 39% 
malformation rate, while the malformation rate at 800 mg/kg was 94%; B6D2 fetuses exposed to 
600 mg/kg VPA had a 91% malformation rate. Interestingly, for rib malformations the difference 
between saline- and VPA-exposed fetuses was greater in the D2B6 genotype compared to the 
B6D2 genotype (p < .03; Table 2). In this case, the D2 genotype and/or uterine environment 
increased susceptibility to rib malformations. 
Western Blots and Quantitative PCR 
Valproic acid is a histone deacetylase inhibitor and increased histone acetylation/deacetylation 
inhibition has been linked to VPA teratogenesis (Eikel et al., 2006; Menegola et al., 2005). It is 
possible that the differences in VPA teratogenesis observed in B6 and D2 are due, at least in part, 
to strain differences in VPA-induced acetylation/deacetylation inhibition. Therefore, we 
examined acetylation of histone proteins H3 and H4 in both placenta and embryo following 
intrauterine VPA or ethanol exposure. We chose H3 and H4 because  most previous studies that 
have examined acetylation/deacetylation with VPA have examined these two histone proteins 
and not H1, H2A or H2B. There were no differences in band intensity in histones H3 or H4, 
either among treatments or between strains, so band densities for acetylated H3 (H3ac) or 
acetylated H4 (H4ac) were normalized to H3 or H4.  
Compared to maltose-treated controls, embryos from both strains exhibited a similar increase 
in acetylated H3 (H3ac) following prenatal VPA (98-101%) and prenatal ethanol (57-64%; 
Figure 1). D2 embryos showed a greater increase in acetylated H4 (H4ac) compared to B6 
following VPA (97% vs. 40%; p < .01; Figure 2). Following prenatal alcohol exposure, D2 
embryos had a 44% increase in H4ac (p < .01; Figure 2), while B6 embryos actually showed a 
slight decrease. Increases in acetylation were smaller in placenta, compared to embryo, following 
in utero VPA or ethanol exposure (Figures 1-4). B6 placentae had a 93% increase in H3ac 
following prenatal VPA, compared to 51% for D2 (p < .02); the increases in H3ac following 
prenatal alcohol were 37% and 18%, respectively (Figure 3). Following in utero VPA, B6 and 
D2 had similar increases in H4ac in placentae, but D2 had a larger increase than B6 following 
prenatal alcohol (63% vs. 32%, p < .05; Figure 4).                
Valproic acid preferentially inhibits class I (1, 2, 3 and 8) histone deacetylases (Gottlicher et al. 
2001). It is possible that if VPA inhibits histone deacetylation and effectively increases 
acetylation, and HDAC inhibition/increased acetylation is correlated with teratogenesis, there 
would be a compensatory increase in HDAC mRNA and protein. In culture, VPA has been 
shown to increase expression of several HDAC mRNAs (Kim, et al., 2008). Therefore, we 
examined expression of Hdac1, Hdac2, Hdac3 and Hdac8 in embryo and placenta following in 
utero exposure to maltose, ethanol or VPA. We also examined expression of Hdac4 because it 
plays a role in skeletal development (Vega et al., 2004). Cycle threshold values were normalized 
to Gapdh and relative fold changes were determined in comparison to maltose-treated controls. 
Fold changes were small, ranging from a 0.31-fold increase to a 0.22-fold decrease. There were 
no significant fold changes in any of the Hdac genes in either strain (placenta or embryo) 
following prenatal VPA or alcohol.  
 
Discussion 
Valproic acid (VPA) is one of the most frequently used drugs to treat epilepsy, bipolar disorder 
and migraine headaches, but VPA is teratogenic. While few studies have looked for genetic 
variation in susceptibility to VPA teratogenesis in humans, several studies have demonstrated 
genetic variation in mice. We found that following intrauterine VPA exposure, fetuses from 
C57BL/6J (B6) and DBA/2J (D2) inbred strains of mice showed altered skeletal development, 
but differed in degree of susceptibility to specific malformations. While B6 fetuses showed an 
increase in fused and missing digits at the highest dose of VPA, D2 fetuses were resistant to digit 
malformations. Rib development was altered in both strains, but the effect was greater in D2 
fetuses. In contrast, while vertebral development was also altered in both strains, the effect was 
greater in B6 fetuses. Results from our study agree with Faiella et al. (2000), who reported that 
B6 fetuses were more susceptible to digit and vertebral malformations than D2 following in 
utero VPA, while D2 fetuses was more susceptible to rib malformations. These studies have 
identified genetic variation in response to prenatal VPA but do not reveal to what extent maternal 
and embryonic genes play a role in teratogenesis.  
One simple strategy for determining maternal and fetal genetic contribution is to reciprocally 
cross two inbred strains. If the reciprocally bred, genetically identical F1 offspring differ on the 
trait, this is known as a maternal effect and suggests that maternal genotype can play an 
important role in the trait. We found that F1 offspring carried in a B6 mother were more 
susceptible to vertebral malformations than F1 offspring carried in a D2 mother, while F1 
offspring carried in a D2 mother were more susceptible to rib malformations. Beck (1999, 2001) 
reported a maternal effect following in utero VPA, with fetuses carried in a B6 mother being 
comparatively resistant to exencephaly, compared to fetuses carried in susceptible SWV 
mothers. In a reciprocal cross between D2 and P/J inbred mice, fetuses carried in a D2 mother 
were relatively resistant to vertebral malformations (Faiella et al., 2000). These findings indicate 
that maternal effects can be an important determinant of VPA teratogenesis and the same 
maternal genotype/uterine environment can increase susceptibility to some teratogenic effects 
but not others. Embryo transfers can be used to evaluate the effects of uterine environment.  
One potential mechanism that can account for a maternal effect is genomic imprinting, an 
epigenetic phenomenon in which only one of two parental alleles at a locus is expressed. At the 
molecular level, genomic imprinting is mediated in large part by differential DNA methylation 
and covalent modification of histone proteins. One of the best characterized histone 
modifications is acetylation, where acetyl groups are attached to histones by histone 
acetyltransferases (HATs) and removed by histone deacetylases (HDACs). HDACs have been 
shown to play a role in somitogenesis, skeletogenesis and limb/digit development (Morrison and 
D’Mello, 2008; Westendorf, 2007). Valproic acid is a HDAC inhibitor (HDACi) and increases 
acetylation, an effect that is correlated with its’ teratogenic properties (Menegola et al. 2005). It 
is possible that the differential teratogenesis in B6 and D2 fetuses is due, at least in part, to 
differential HDACi activity of VPA in these two strains. As a first step in testing this hypothesis, 
we examined acetylation of lysine residues on histones H3 and H4 following in utero exposure 
to VPA. Embryos from both strains showed a nearly two-fold increase in H3ac following 
intrauterine exposure to VPA. While D2 embryos also showed a nearly two-fold increase in 
H4ac, the increase in B6 was much smaller. In placenta, where overall acetylation levels were 
higher, the increases in acetylation following VPA exposure were smaller and the strain 
differences were reversed. Both strains showed similar increases in H4ac, while B6 had a nearly 
two-fold increase in H3ac compared to D2. These strain differences in acetylation following in 
utero VPA exposure need to be examined in greater depth before the relationship between 
differential acetylation/deacetylation and teratogenesis can be determined. 
Analogs of VPA that have HDACi activity are teratogenic, while analogs of VPA that do not 
have HDACi activity are not teratogenic (Eikel et al., 2006; Gurvich et al., 2005). Furthermore, 
other teratogens such as sodium salicylate, sodium butyrate, apicidin, the synthetic benzamide 
derivative MS-275, and boric acid all have HDACi activity and produce similar vertebral 
malformations (Di Renzo et al., 2007a, 2007b, 2008). This provides convincing evidence that 
histone acetylation/deacetylation can play an important role in vertebral teratogenesis. Given that 
alcohol produces similar vertebral malformations when administered in utero, we examined 
histone acetylation in B6 and D2 following prenatal alcohol exposure. There were increases in 
H3ac and H4ac in both embryo and placenta following prenatal alcohol exposure but the 
increases were clearly not as large as those observed with VPA. This suggests that, prenatally, 
alcohol does not have as great of HDACi activity as VPA, although other mechanisms for 
increased acetylation may be responsible, as discussed below. The only strain difference in 
acetylation that was consistent between VPA and ethanol was a greater increase in H4ac in D2 
embryos compared to B6 embryos.  
Our study is a first step towards characterizing genetic variation in teratogenesis and histone 
acetylation/deacetylation following prenatal VPA exposure. One shortcoming of our study is that 
we did not examine VPA metabolism in pregnant dams or embryos. It is possible that strain 
differences in VPA metabolism could contribute, at least in part, to strain differences in VPA 
teratogenesis. To the best of our knowledge, no studies have looked at VPA metabolism in 
pregnant B6 or D2 dams or embryos.  Additional studies are also needed to clarify the role that 
increased acetylation and deacetylase inhibition play in VPA teratogenesis. We observed 
changes in global acetylation but it is likely that there are specific regions of the genome, 
perhaps imprinted loci, where histone acetylation/deacetylation plays a crucial role in VPA 
teratogenesis. Chromatin immunoprecipitation assays can be used to interrogate acetylation in 
specific genomic regions. Acetylation levels will also need to be measured at different time-
points following VPA exposure and in more specific tissues (i.e., developing vertebra). While 
studies often infer HDACi activity by observing increased acetylation, assays that measure the 
rate of deacetylation are available and can be used to assess the extent to which increased 
acetylation is due to HDACi activity. Levels of HATs and HAT activity will also need to be 
examined.                     
Acetylation and HDAC inhibition may play a role in differential susceptibility to VPA 
teratogenesis, but additional mechanisms are almost certainly involved. Observing genetic 
variation will identify strains for further investigation but does not provide information on causal 
genes, polymorphisms or genetic pathways. Quantitative trait locus (QTL) mapping can be used 
to identify regions on chromosomes that harbor genes or DNA polymorphisms mediating 
variation in VPA teratogenesis. B6 and D2 have been two of the most frequently used inbred 
strains in biomedical research and their genomes have been extensively sequenced. This makes 
lines of mice derived from B6 and D2, such as the BXD recombinant inbred (RI) strains, a 
valuable resource for QTL mapping. There is a high degree of synteny and homology between 
mouse and human genomes, so putative causal polymorphisms and epigenetic modifications 
identified in mice can be examined in humans. Given the paucity of research investigating 
genetic variation in humans, mice will be a valuable tool for elucidating genetic mechanisms 
mediating susceptibility to VPA teratogenesis.    
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Figure 1. Western blot for acetylated histone H3 (H3ac) in embryo following in utero exposure 
to valproic acid (VPA) or ethanol. There were no differences in H3 among treatments or 
between strains, so band densities for each sample were normalized to H3. Results are 
presented as the percent change from maltose-treated controls. * indicates a significant 
increase compared to maltose control, p < .01.  
Figure 2. Western blot for acetylated histone H4 (H4ac) in embryo following in utero exposure 
to valproic acid (VPA) or ethanol. There were no differences in H4 among treatments or 
between strains, so band densities for each sample were normalized to H4. Results are 
presented as the percent change from maltose-treated controls. * indicates a significant 
increase compared to maltose controls, p < .01; **, p < .05.  
Figure 3. Western blot for H3ac in placenta. Band densities for acetylated H3ac were normalized 
to H3 for each sample and results are presented as the percent change from maltose-treated 
controls. * indicates a significant increase, p < .01; **, p < .05.   
Figure 4. Western blot for H4ac in placenta. Band densities for acetylated H4ac were normalized 
to H4 for each sample and results are presented as the percent change from maltose-treated 
controls. * indicates a significant increase, p < .01. 
 
     
